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INTRODUCTION
Autism is a life-long developmental disability 
which can affect communication, social interaction, 
and behaviour. Its clinical form and severity can vary 
from person to person, however, people with autism 
share some difficulty in making sense of the world. 
First illustrated in a series of case histories by Leo 
Kanner in 1943, it was not until 1980 that autism was 
officially recognized as a disorder of development 
distinct from childhood schizophrenia (18).
Subjects with features similar to classic, Kanner-
type autism have been identified who do not fulfil 
the same specific criteria for autism. To recognise 
this, a broader range of pervasive developmental 
disorders including Asperger’s syndrome, pervasive 
developmental disorder - not otherwise specified 
(PDD NOS)/atypical autism are now considered to be 
part of the autistic spectrum (although classification 
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is contentious). This is as a whole known as autism 
spectrum disorder (ASD). 
Core features of ASD are evident in three of the 
following behavioural areas (7):
1. Social interaction - general difficulty with 
and lack of interest in developing social 
relationships. Not understanding fully the 
meaning of gestures, facial expressions, body 
postures, voice tone, and social cues to convey 
meaning and regulate social interactions. An 
absence of insight into what the other person 
is thinking (lacking in a ‘theory of mind’) or 
feeling (empathy).
2. Language and communication - language 
deficits lead to a delay or limitations in 
speech, including muteness in some people 
and difficulty in initiating or sustaining a 
conversation with others. Stereotyped and 
repetitive use of language which can be very 
literal, idiosyncratic and overly formal, marked 
by ‘over-learned scripts’. Speech is used to 
communicate needs and provide information 
rather than to exchange information or for 
social conversation. 
3. Restrictive interests and repetitive behaviour 
- rigid and repetitive behaviour patterns 
including non-functional routines or rituals 
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(e.g., touching doorknobs or walls). Inflexible 
adherence to behaviour and resistance to change 
in routine or to being interrupted. Stereotyped 
and repetitive motor mannerisms such as ‘hand 
flapping’ when aroused or behaviours which 
are pleasurable such as spinning car wheels or 
watching the same video repeatedly, and oral 
stereotyped movements such as humming or 
incessant questioning. 
Associated ASD features sometimes evident 
include the following (2):
 ❖ unprovoked aggressive or violent behaviour to 
self and others such as biting, head-banging 
and gouging;
 ❖ attention and concentration problems;
 ❖ sleep disturbance and a decreased need for 
sleep;
 ❖ unusual responses to sensory stimuli, and
 ❖ special skills and interests such as a talent for 
music, mathematics, visual-spatial abilities, or 
an exceptional memory for areas of knowledge 
of particular interest. Some individuals may 
have an outstanding rote visual or auditory 
memory and a high IQ.
The triad of core features described above is the 
basis for the diagnostic criteria used by the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-
IV) (1) and the International Classification of 
Diseases (ICD-10) (19) to classify ASD (Table 1). 
The aim of this study is to present a literature 
review about the treatment of humans with autism 
and to identify the most effective drugs of best 
practice in ASD treatment. 
The goal in using medications is to reduce 
behaviours, thoughts, or emotions that interfere with 
education or social interaction and distress of child 
or others.
As a result, medications may improve the effect 
of non-medication therapies. 
New medications are being developed all the 




A variety of drugs are administered to treat 
or manage symptoms and associated conditions of 
autism. 
Typical antipsychotics
Several studies are devoted too various 
typical antipsychotics including haloperidol (5) 
and pimozide (12). While both are considered to 
be efficacious, concerns about the development 
of dyskinesias including tardive dyskinesia (TD) 
have meant that usage of typical antipsychotics, 
particularly haloperidol, has usually been reserved 
for individuals with severe symptoms. One of the 
benefits of haloperidol is that weight change is a less 
common side effect of treatment.
Atypical antipsychotics
Atypical antipsychotics are recognized for 
their ability to produce an antipsychotic effect in a 
majority of patients without inducing significant 
extrapyramidal side effects. These effects include 
both early-onset and chronic neurological adverse 
events involving voluntary and involuntary 
musculature, the most common of which include 
parkinsonism (bradykinesia, rigidity, tremor), 
dystonias, and akathisia. Neuroleptic malignant 
syndrome is another major acute side effect that may 
be associated with the use of antipsychoticm drugs 
such as neuroleptics. It is typically characterised by 
severe muscular rigidity, fever, an altered level of 
consciousness, and autonomic instability. Atypical 
antipsychotics, i.e. potent antagonists of serotonin 














Table 1. Diagnoses relevant to ASDs
Scripta Scientifica Medica, vol. 45, No 2, 2013, pp. 11-16
Copyright © Medical University of Varna   13
Svetlana Georgieva, Yana Koleva
lower TD incidence rate in the short term, and 
clinicians began to use them more often when 
treating the individuals with autism. 
Risperidone is effective in improving the 
hyperactivity and reducing the frequency and 
intensity of temper outbursts and aggression, which 
are sometimes apparent as associated symptoms of 
people with autism, although there are concerns 
about its side effects such as sedation and weight gain 
(11). At higher doses, extrapyramidal side effects may 
occur more frequently.
Olanzapine has been used for treatment of 
aggression, hyperactivity, mood symptoms, sleep 
disturbances and psychosis in patients with autism 
(14). Weight gain may be a problematic side effect 
with this medication, too.
Clozapine usage has been described in a small 
case study of only three children (20). Its limited 
use to date may relate to the need for frequent tests 
to monitor leukocyte counts due to the risk of 
agranulocytosis as well as to a higher risk of seizures 
at high doses. This is particularly noteworthy as 
individuals with autism are already at higher than 
normal risk of developing seizure disorders.
Antidepressants
A wide variety of antidepressant medications are 
used in the treatment of autism for decades. This drug 
class comprises a broad group of chemical compounds 
that generally work by increasing the concentration in 
the synaptic space primarily of noradrenaline and/or 
serotonin (5-HT). Researchers investigate whether the 
selective serotonin re-uptake inhibitors (SSRIs) may 
be of benefit in reducing the repetitive behaviours, 
aggression and aspects of social relatedness in 
children, adolescents, and adults with autism. These 
medications are considered safer alternatives than the 
tricyclic antidepressants, given their better tolerability 
and lack of significant cardiac effects.
Clomipramine is a tricyclic antidepressant 
recognized for its potent inhibition of 5-HT uptake, 
i.e., acting as a non-selective SRI. It is more efficacious 
than the relatively selective noradrenaline-reuptake-
inhibiting tricyclic desipramine in the treatment 
of children with obsessive-compulsive disorder 
(10). The repetitive behaviours and stereotyped 
movements commonly seen in PDD including ASD 
resemble, in part, the compulsions observed in 
this disorder. Clomipramine efficacy is studied in 
children, adolescents and adults with autism. There 
is some suggestion that this drug could be better 
tolerated by adolescents and adults than by children.
As potent inhibitors of 5-HT uptake, SSRIs such 
as fluvoxamine have received increasing attention as 
a treatment option for autistic symptoms because of 
their better side effect profiles compared to tricyclics 
such as clomipramine. Fluvoxamine appears to target 
a range of symptoms including repetitive thoughts 
and behaviour, maladaptive behaviour, aggression, 
and communicative use of language. However, its 
lower efficacy and tolerability has been established 
in children and adolescents with autism (17). 
Other examples of antidepressant medication 
such as imipramine, trazodone, bupropion, 
venlafaxine, nefazadone, monoamine-oxidase 
inhibitors (MAOIs) and mirtazapine may be used for 
managing ASD symptoms. 
Fenfluramine
Fenfluramine is an indirect 5-HT receptor 
agonist with structural similarities to amphetamine. 
Several initial reports indicate that this agent is 
promising as a potential treatment for autism. An 
initial double-blind crossover study of fenfluramine 
and placebo displays favourable results. However, 
subsequent double-blind placebo-controlled trials 
failed to show consistent benefits with fenfluramine 
use in children. Approved by the Food and Drug 
Administration (FDA) for the treatment of obesity, 
the drug is voluntarily withdrawn from the world 
market in 1997 because of concern that it contribute 
to the development of cardiac valvular disease (13).
Stimulants
Early studies of the effects of stimulants in 
children with autism generally produce negative 
results. There are concerns about the possibility that 
stimulants may lower the seizure threshold. This 
leads to the widespread clinical view that stimulants 
are contraindicated in treating autism (13). However, 
some preliminary studies with children suggest 
positive benefits with stimulant treatment relating to 
motor hyperactivity and inattention in autism.
Anticonvulsants
It remains unclear whether anticonvulsants 
such as lamotrigine may be helpful in improving 
other clinical symptoms of autism in adolescents 
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and adults, in addition to their effects in controlling 
seizure disorders (3) although some preliminary 
work with sodium valproate is promising.
Lithium
Lithium is an alkaline metal salt that acts on 
multiple neurotransmitter systems. This agent could 
be effective for some individuals with ASD where 
there are symptoms resembling mania and positive 
family histories of bipolar disorder (9).
Anxiolytics
Buspirone is a 5-HT1A receptor partial agonist 
used in the treatment of a generalized anxiety 
disorder that may improve target symptoms of 
anxiety and irritability in the patients with PDD 
including autism, too (4).
α2-Adrenergic agonists
Guanfacine is applied to improve hyperactivity, 
inattention, insomnia and tics in individuals with 
autism (17). 
β-Adrenergic antagonists
Propanolol is used in treating aggression and 
self-injury in adults with autism and exerts a positive 
effect on socialization and speech (15).
Opiate antagonists
Excess opiate activity is mooted as a contributing 
factor to the aberrant social and language 
development observed in individuals with autism. 
The opiate antagonist naltrexone hydrochloride 
is investigated for its efficacy in treating the core 
symptoms of autism and reducing the self-injurious 
behaviour (17).
Miscellaneous
Secretin, a gastrointestinal polypeptide 
hormone, is an agent recently received attention 
as a possible pharmacological treatment for ASD. 
Porcine secretin as well as synthesized human 
secretin administered intravenously is applied. 
Originally FDA-approved for use in the diagnosis of 
certain gastrointestinal diseases, secretin’s use for the 
treatment of autism is popularized by a small study 
that reports its positive impact on language and social 
relatedness in three small children with autism (8). 
Vancomycin and intravenous immunoglobulin 
are investigated to reveal if their usage results in any 
behavioural improvements in children with autism 
(16).
There are claims that ‘mega’ dosages of certain 
vitamins and other agents could ameliorate or 
prevent a range of pathoilogical conditions including 
ASD. Such agents include vitamin B6, vitamin 
B12, folic acid, magnesium and melatonin. In 
general, vitamins act as coenzymes or enhancers of 
biochemical processes, many of which are involved 
in the synthesis and regulation of neurotransmitters 
and other polypeptide products. High doses of 
vitamins, especially pyridoxine or vitamin B6 in 
conjunction with magnesium are proposed as being 
helpful in autism by reducing the aggressiveness, 
self-stimulation, and avoidance of eye contact, and 
improving the social relatedness and speech. Mega 
dosages of vitamins are variable in their toxicity, 
depending on the vitamin used. So, the effectiveness 
of vitamin therapy is questioned (6).
DIRECTIONS FOR FUTURE 
RESEARCH
Future research should attempt to address the 
methodological limitations in study of ASD and they 
are expected to lead to better quality of life of the 
patients with ASD.
Some features of future research are briefly 
presented below:
 ❖ Consideration of a broader range of 
pharmacological interventions and trials 
comparing clinically acceptable drugs;
 ❖ Studies comparing pharmacological 
interventions within and between drug classes, 
including polypharmacy;
 ❖ Studies systematically comparing multiple 
therapies (pharmacological, behavioral, and 
educational) or combinations of these;
 ❖ Studies with longer follow-up periods for 
assessing outcomes post-treatment, particularly 
safety outcomes, given that autism is a chronic 
condition and long periods of treatment are to 
be expected;
 ❖ Studies with multivariate analyses to investigate 
the effects of potentially confounding factors in 
intervention effectiveness;
 ❖ More generally, studies are required of the 
differences between subtypes of autism across 
ASD as well as of the varying treatment and 
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support needs of these distinct diagnostic 
groups;
 ❖ With respect to multiple pharmacotherapy 
interventions, drugs that may treat one 
symptom may exacerbate another, requiring 
the development of more selective agents, and
 ❖ Molecular genetic studies of extensive interest 
may lead to the development of new and 
effective treatments.
CONCLUSION
Whilst autism currently cannot be cured, 
pharmacological interventions are utilized to assist in 
managing the symptoms and associated conditions 
of autism. These may be problematic for the person 
with autism and/or their carers. Such treatments 
may also enhance the benefit from other concurrent 
therapies which include behaviour modification and 
other psychosocial and educational interventions. 
Medications are rarely the sole treatment modality 
for any individuals with autism. As an adjunctive 
treatment they may be effective with relatively 
few and manageable side effects, although to date 
evidence is very limited. Many medications that 
appear promising in small, open-label studies are not 
studied under reliable experimental conditions in 
any age group yet. 
While more research is required of agents 
that target associated symptoms interfering with 
functioning or causing distress, development and 
evaluation of promising medications concerning the 
treatment of core symptoms of social and language 
impairment in ASD should be a priority, too.
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